Abstract
Exenatide: A new promising antidiabetic agent
Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela-769 015, India
Correspondence Address:
C K Chakraborti Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela-769 015 India E-mail: chandrakanti_12@rediffmail.com
Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the destruction of islet beta-cells, type 2 diabetes mellitus patients are not rapidly converted to type 1 diabetes mellitus and ultimately appearance of complications of the disease is halted or delayed. Its long-acting-release formula, which would be used once per week, simultaneously retaining all the properties of twice-daily subcutaneous administration, is undergoing clinical trial. This drug is considered as an adjunct to metformin/sulfonylureas/insulin.
